Flex Pharma Company Profile (NASDAQ:FLKS)

About Flex Pharma

Flex Pharma logoFlex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company's product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company's lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: FLKS
  • CUSIP:
Key Metrics:
  • Previous Close: $11.93
  • 50 Day Moving Average: $11.41
  • 200 Day Moving Average: $10.64
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.89
  • P/E Growth: 0.00
  • Market Cap: $188.09M
  • Outstanding Shares: 15,766,000
  • Beta: 2.98
Additional Links:
Companies Related to Flex Pharma:

Analyst Ratings

Consensus Ratings for Flex Pharma (NASDAQ:FLKS) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $24.00 (101.17% upside)

Analysts' Ratings History for Flex Pharma (NASDAQ:FLKS)
Show:
DateFirmActionRatingPrice TargetDetails
8/18/2016Piper Jaffray Cos.Set Price TargetBuy$25.00View Rating Details
6/10/2016Jefferies GroupReiterated RatingBuy$25.00View Rating Details
6/3/2016HC WainwrightReiterated RatingBuyView Rating Details
5/26/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details
4/12/2016Roth CapitalLower Price Target$27.00 -> $24.00View Rating Details
2/23/2015JMP SecuritiesInitiated CoverageOutperform$30.00View Rating Details
(Data available from 8/24/2014 forward)

Earnings

Earnings History for Flex Pharma (NASDAQ:FLKS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2016        
8/3/2016Q216($0.67)($0.71)$12.69 millionViewListenView Earnings Details
5/4/2016Q1($0.56)($0.61)ViewListenView Earnings Details
3/8/2016Q415($0.56)($0.51)ViewListenView Earnings Details
11/4/2015Q315($0.44)($0.53)ViewListenView Earnings Details
8/5/2015Q215($0.37)($0.47)ViewListenView Earnings Details
5/6/2015Q1($0.29)($0.59)ViewListenView Earnings Details
3/17/2015Q4($0.12)($1.82)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Flex Pharma (NASDAQ:FLKS)
Current Year EPS Consensus Estimate: $-2.65 EPS
Next Year EPS Consensus Estimate: $-3.07 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.46)($0.46)($0.46)
Q2 20162($0.62)($0.52)($0.57)
Q3 20162($0.71)($0.61)($0.66)
Q4 20162($0.76)($0.73)($0.75)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Flex Pharma (NASDAQ:FLKS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Flex Pharma (NASDAQ:FLKS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/23/2016Christoph H WestphalCEOBuy2,700$11.28$30,456.00View SEC Filing  
6/22/2016Christoph H WestphalCEOBuy5,700$11.05$62,985.00View SEC Filing  
6/21/2016Christoph H WestphalCEOBuy2,800$11.07$30,996.00View SEC Filing  
6/20/2016Christoph H WestphalCEOBuy6,000$11.18$67,080.00View SEC Filing  
6/16/2016Christoph H WestphalCEOBuy5,800$11.17$64,786.00View SEC Filing  
6/14/2016Christoph H WestphalCEOBuy5,900$11.54$68,086.00View SEC Filing  
6/10/2016Christoph H WestphalCEOBuy6,000$11.94$71,640.00View SEC Filing  
6/8/2016Christoph H WestphalCEOBuy5,900$12.25$72,275.00View SEC Filing  
6/6/2016Christoph H WestphalCEOBuy6,000$12.56$75,360.00View SEC Filing  
6/2/2016Christoph H WestphalCEOBuy10,000$12.99$129,900.00View SEC Filing  
5/31/2016Christoph H WestphalCEOBuy22,300$12.68$282,764.00View SEC Filing  
5/26/2016Christoph H WestphalCEOBuy28,600$12.84$367,224.00View SEC Filing  
5/24/2016Christoph H WestphalCEOBuy30,334$12.42$376,748.28View SEC Filing  
5/20/2016Christoph H WestphalCEOBuy7,914$11.06$87,528.84View SEC Filing  
5/18/2016Christoph H WestphalCEOBuy33,400$11.10$370,740.00View SEC Filing  
5/16/2016Christoph H WestphalCEOBuy15,469$10.25$158,557.25View SEC Filing  
5/12/2016Christoph H WestphalCEOBuy30,217$10.12$305,796.04View SEC Filing  
5/10/2016Christoph H WestphalCEOBuy30,109$9.94$299,283.46View SEC Filing  
3/24/2016Christoph H WestphalCEOBuy49,563$11.06$548,166.78View SEC Filing  
3/22/2016Christoph H WestphalCEOBuy23,951$11.78$282,142.78View SEC Filing  
3/21/2016Christoph H WestphalCEOBuy48,058$11.74$564,200.92View SEC Filing  
3/18/2016Christoph H WestphalCEOBuy37,574$11.00$413,314.00View SEC Filing  
3/16/2016Christoph H WestphalCEOBuy38,379$10.23$392,617.17View SEC Filing  
3/15/2016Michelle StacyDirectorBuy2,585$9.63$24,893.55View SEC Filing  
3/14/2016Thomas WesselInsiderBuy20,000$7.94$158,800.00View SEC Filing  
3/11/2016Christoph H WestphalCEOBuy89,680$7.00$627,760.00View SEC Filing  
3/11/2016Roderick MackinnonDirectorBuy10,000$7.03$70,300.00View SEC Filing  
12/14/2015Christoph H WestphalCEOBuy927$12.01$11,133.27View SEC Filing  
12/7/2015Christoph H WestphalCEOBuy907$12.02$10,902.14View SEC Filing  
11/19/2015Marc D KozinDirectorBuy4,500$11.38$51,210.00View SEC Filing  
11/16/2015Christoph H WestphalCEOBuy1,001$10.78$10,790.78View SEC Filing  
11/9/2015Christoph H WestphalCEOBuy1,000$11.03$11,030.00View SEC Filing  
10/26/2015Christoph H WestphalCEOBuy1,043$10.55$11,003.65View SEC Filing  
10/19/2015Christoph H WestphalCEOBuy1,018$10.61$10,800.98View SEC Filing  
9/28/2015Christoph H WestphalCEOBuy924$11.18$10,330.32View SEC Filing  
3/30/2015Christoph H WestphalCEOBuy272$20.52$5,581.44View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Flex Pharma (NASDAQ:FLKS)
DateHeadline
News IconCrowd & Street Monitoring Flex Pharma, Inc. (NASDAQ:FLKS) Shares - Post News (NASDAQ:FLKS)
www.kentuckypostnews.com - August 23 at 9:24 AM
News IconStock Tracking Lower for the Quarter: Flex Pharma, Inc. (NASDAQ:FLKS) - Post News (NASDAQ:FLKS)
www.kentuckypostnews.com - August 21 at 9:30 AM
investornewswire.com logoWill Flex Pharma, Inc. (NASDAQ:FLKS) Hit $40 Price Target? - Investor Newswire (NASDAQ:FLKS)
www.investornewswire.com - August 21 at 9:30 AM
investornewswire.com logoWill Flex Pharma, Inc. (NASDAQ:FLKS) Surprise Analysts? - Investor Newswire (NASDAQ:FLKS)
www.investornewswire.com - August 17 at 8:00 AM
realistinvestor.com logoAnalysts See Flex Pharma, Inc. (NASDAQ:FLKS) Reporting EPS Of $-0.85 - RealistInvestor.com (NASDAQ:FLKS)
www.realistinvestor.com - August 16 at 8:20 AM
finance.yahoo.com logoFLEX PHARMA, INC. Financials (NASDAQ:FLKS)
finance.yahoo.com - August 11 at 5:12 PM
finance.yahoo.com logoEdited Transcript of FLKS earnings conference call or presentation 3-Aug-16 12:45pm GMT (NASDAQ:FLKS)
finance.yahoo.com - August 4 at 5:20 PM
businesswire.com logoFlex Pharma Reports Second Quarter 2016 Financial Results (NASDAQ:FLKS)
www.businesswire.com - August 3 at 5:20 PM
sg.finance.yahoo.com logoFlex Pharma reports 2Q loss (NASDAQ:FLKS)
sg.finance.yahoo.com - August 3 at 5:20 PM
biz.yahoo.com logoFLEX PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition (NASDAQ:FLKS)
biz.yahoo.com - August 3 at 5:20 PM
finance.yahoo.com logoFlex Pharma to Report Second Quarter 2016 Results on August 3, 2016 - Yahoo Finance (NASDAQ:FLKS)
finance.yahoo.com - July 27 at 5:16 PM
publicnow.com logoFlex Pharma to Report Second Quarter 2016 Results on August 3, 2016 (NASDAQ:FLKS)
www.publicnow.com - July 27 at 8:58 AM
4-traders.com logoFlex Pharma : Completes Enrollment of Human Proof-of Concept Efficacy Study in Nocturnal Leg Cramps (NASDAQ:FLKS)
www.4-traders.com - July 26 at 11:11 PM
finance.yahoo.com logoFlex Pharma Completes Enrollment of Human Proof-of Concept Efficacy Study in Nocturnal Leg Cramps - Yahoo Finance (NASDAQ:FLKS)
finance.yahoo.com - July 26 at 5:04 PM
publicnow.com logoFlex Pharma Completes Enrollment of Human Proof-of Concept Efficacy Study in Nocturnal Leg Cramps (NASDAQ:FLKS)
www.publicnow.com - July 26 at 8:18 AM
ftsenews.co.uk logoNew Broker Ratings For Flex Pharma, Inc. (FLKS) - FTSE News (NASDAQ:FLKS)
www.ftsenews.co.uk - July 26 at 6:12 AM
investornewswire.com logoIs $40 Price Target Attainable For Flex Pharma, Inc. (NASDAQ:FLKS)? - Investor Newswire (NASDAQ:FLKS)
www.investornewswire.com - July 24 at 9:33 AM
News IconFlex Pharma, Inc. (NASDAQ:FLKS): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:FLKS)
www.engelwooddaily.com - July 22 at 5:55 AM
News IconCould Flex Pharma Inc Change Direction After Today's Huge Increase? - Consumer Eagle (NASDAQ:FLKS)
www.consumereagle.com - July 21 at 8:34 AM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Flex Pharma, Inc. (NASDAQ:FLKS) - TGP (NASDAQ:FLKS)
telanaganapress.com - July 19 at 10:18 PM
News IconEquity Roundup: Stock Performance Focus on Flex Pharma, Inc. (NASDAQ:FLKS) - Press Telegraph (NASDAQ:FLKS)
presstelegraph.com - July 19 at 10:18 PM
News IconInvestor Watch: Volatility Recap on Shares of: Flex Pharma, Inc. (NASDAQ:FLKS) - Engelwood Daily (NASDAQ:FLKS)
www.engelwooddaily.com - July 18 at 5:13 PM
News IconInsider Trader Watch: Flex Pharma Inc (NASDAQ:FLKS) - The Voice Registrar (NASDAQ:FLKS)
voiceregistrar.com - July 18 at 5:13 PM
investornewswire.com logoStrong Sell Calls For Flex Pharma, Inc. (NASDAQ:FLKS) At 0 - Investor Newswire (NASDAQ:FLKS)
www.investornewswire.com - July 17 at 4:42 PM
fiscalstandard.com logoNext Weeks Broker Price Targets For Flex Pharma, Inc. (FLKS) - Fiscal Standard (NASDAQ:FLKS)
www.fiscalstandard.com - July 17 at 4:42 PM
News IconFlex Pharma, Inc. (NASDAQ:FLKS) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:FLKS)
www.engelwooddaily.com - July 14 at 10:23 PM
News IconEye on Stock Volatility for: Flex Pharma, Inc. (NASDAQ:FLKS) - Engelwood Daily (NASDAQ:FLKS)
www.engelwooddaily.com - July 14 at 10:23 PM
News IconAnalyst Target and Average Rating Watch: Flex Pharma, Inc. (NASDAQ:FLKS) - Press Telegraph (NASDAQ:FLKS)
presstelegraph.com - July 14 at 8:22 AM
News IconInsiders Increasing Positions in: Flex Pharma, Inc. (NASDAQ:FLKS) - Press Telegraph (NASDAQ:FLKS)
presstelegraph.com - July 14 at 8:22 AM
News IconShare Volatility Watch for: Flex Pharma, Inc. (NASDAQ:FLKS) - Engelwood Daily (NASDAQ:FLKS)
www.engelwooddaily.com - July 13 at 5:23 PM
wsj.com logoA New Way to Prevent Muscle Cramps (NASDAQ:FLKS)
www.wsj.com - July 12 at 10:23 PM
News IconFlex Pharma, Inc. (NASDAQ:FLKS) Wall Street Analyst Recommendation Outlook - Telanagana Press (NASDAQ:FLKS)
telanaganapress.com - July 12 at 9:28 AM
investornewswire.com logoIs $40 Within Reach For Flex Pharma, Inc. (NASDAQ:FLKS)? - Investor Newswire (NASDAQ:FLKS)
www.investornewswire.com - July 10 at 9:32 AM
fiscalstandard.com logoFlex Pharma, Inc. (FLKS) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:FLKS)
www.fiscalstandard.com - July 10 at 9:32 AM
News IconCan Flex Pharma, Inc. (NASDAQ:FLKS) Improve on the Earnings Front? - Engelwood Daily (NASDAQ:FLKS)
www.engelwooddaily.com - July 8 at 6:16 AM
fiscalstandard.com logoBroker Outlook For Flex Pharma, Inc. (FLKS) - Fiscal Standard (NASDAQ:FLKS)
www.fiscalstandard.com - July 8 at 6:16 AM
News IconCompany Stock Focus for Flex Pharma, Inc. (NASDAQ:FLKS): Which Way Will Shares Head? - Press Telegraph (NASDAQ:FLKS)
presstelegraph.com - July 6 at 10:51 PM
News IconPerformance Recap and Target Perspective on Flex Pharma, Inc. (NASDAQ:FLKS) - Press Telegraph (NASDAQ:FLKS)
presstelegraph.com - July 6 at 5:07 PM
fiscalstandard.com logoThis Weeks Broker Price Targets For Flex Pharma, Inc. (FLKS) - Fiscal Standard (NASDAQ:FLKS)
www.fiscalstandard.com - July 6 at 9:45 AM
finance.yahoo.com logoFlex Pharma to Present at the Cantor Fitzgerald Healthcare Conference - Yahoo Finance (NASDAQ:FLKS)
finance.yahoo.com - July 6 at 9:45 AM
publicnow.com logoFlex Pharma to Present at the Cantor Fitzgerald Healthcare Conference (NASDAQ:FLKS)
www.publicnow.com - July 6 at 8:51 AM
investornewswire.com logoFlex Pharma, Inc. (NASDAQ:FLKS) Expected to Reach Highs Of $40 - Investor Newswire (NASDAQ:FLKS)
www.investornewswire.com - July 2 at 4:56 PM
News IconTracking Stock Volatility for: Flex Pharma, Inc. (NASDAQ:FLKS) - Engelwood Daily (NASDAQ:FLKS)
www.engelwooddaily.com - July 1 at 5:02 PM
seekingalpha.com logoFlex Pharma: What A Load Of Cramp - Seeking Alpha (NASDAQ:FLKS)
seekingalpha.com - June 30 at 6:14 AM
News IconCheck on Share Volatility: Flex Pharma, Inc. (NASDAQ:FLKS) - Engelwood Daily (NASDAQ:FLKS)
www.engelwooddaily.com - June 28 at 10:01 PM
News IconFlex Pharma Incorporated (NASDAQ:FLKS) Sellers Increased By 12.96% Their Shorts - Engelwood Daily (NASDAQ:FLKS)
www.engelwooddaily.com - June 26 at 4:36 PM
investornewswire.com logoStrong Sell Calls Recommendations For Flex Pharma, Inc. (NASDAQ:FLKS) At 0 - Investor Newswire (NASDAQ:FLKS)
www.investornewswire.com - June 26 at 4:36 PM
news.cmlviz.com logoFlex Pharma, Inc. (NasdaqGM:FLKS) Stock Momentum Hits Weakness - CML News (NASDAQ:FLKS)
news.cmlviz.com - June 23 at 5:28 AM
fiscalstandard.com logoFlex Pharma, Inc. (FLKS) Analyst Price Targets For The Coming Week - Fiscal Standard (NASDAQ:FLKS)
www.fiscalstandard.com - June 19 at 4:47 PM
marketexclusive.com logoHere's What You Need To Know About The Flex Pharma Inc (NASDAQ:FLKS) MS Trial - Market Exclusive (NASDAQ:FLKS)
marketexclusive.com - June 18 at 9:31 AM

Social

Flex Pharma (NASDAQ:FLKS) Chart for Wednesday, August, 24, 2016


Last Updated on 8/24/2016 by MarketBeat.com Staff